Journal of Clinical Medicine · 6 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study tested two synthetic peptides derived from a plant protein inhibitor in mice, finding that they prolonged the time to arterial thrombus formation and inhibited platelet aggregation without increasing bleeding time in animal models. The main limitation is that all experiments were conducted in vitro or in mice, so direct human clinical effects are not established.
Antithrombotic drugs often increase bleeding risk. Plant-derived protease inhibitors like DrTI from Delonix regia show anticoagulant and antiplatelet effects. Methods: Two synthetic peptides (pDrTI and pDrTI-RI) based on DrTI's sequence were tested in vitro on coagulation proteases and platelet aggregation, and in vivo in mice using photochemical arterial thrombosis, intravital microscopy, and bleeding time assays. Key Results: In vitro, the peptides did not inhibit trypsin but showed high-concentration inhibition of plasma kallikrein (pDrTI) or factor XIa (pDrTI-RI), and inhibited ADP- and arachidonic acid-induced platelet aggregation. In mice, both peptides at 0.5 mg/kg significantly prolonged time to arterial occlusion (pDrTI: 88.6 ± 9 min; pDrTI-RI: 97.8 ± 22 min) versus control (53 ± 7 min), and altered platelet adhesion/aggregation in intravital microscopy without affecting ex vivo aPTT or bleeding time. Limitations: All animal experiments were preclinical; mechanisms of action were not fully characterized. Implications: The peptides demonstrate antithrombotic potential in murine models without impairing hemostasis, suggesting promise for further development, though human relevance requires future investigation.
